SOUTH SAN FRANCISCO, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), which is focused on transforming the treatment and care of people living with sickle cell disease, today announced steps the company is taking to support public health efforts to

SOUTH SAN FRANCISCO, Calif. , March 04, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2020 , the compensation committee of GBT’s board of directors granted four new employees restricted stock units for an aggregate of 15,550 shares of

Obtained FDA approval of Oxbryta ® (voxelotor), the first treatment that specifically targets the root cause of sickle cell disease (SCD), three months ahead of schedule Made Oxbryta available to adults and children 12 years of age and older with SCD within days of FDA approval Maintained strong

SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 40 th Annual Healthcare Conference in Boston on Tuesday, March 3, 2020 , at 12:00 p.m. Eastern Time .

SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that it is accepting proposals for its Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program , which provides grant funding to expand novel

SOUTH SAN FRANCISCO, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2019 , on Wednesday, February 26, 2020 , after U.S.

SOUTH SAN FRANCISCO, Calif. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2020 , the compensation committee of GBT’s board of directors granted seven new employees options to purchase an aggregate of 16,000 shares of the

SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2020 , the compensation committee of GBT’s board of directors granted 7 new employees options to purchase an aggregate of 11,200 shares of the

SOUTH SAN FRANCISCO, Calif. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 38 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 , at 4:00 p.m. Pacific Time .